R-Biopharm flu tests also detect new virus variants

R-Biopharm AG

R-Biopharm flu tests also detect new virus variants

Darmstadt

The flu season has started and different variants of viruses are also circulating in Germany. Thanks to the flu tests from the biotechnology company R-Biopharm, those who get sick quickly have peace of mind: its RIDA®GENE Flu tests also reliably identify two new variants. The company made the announcement in relation to influenza A H1N1pdm09, which is circulating mainly in the UK, and the H3N2 subtype, which broke out in Denmark in the spring and is currently dominating flu events in Germany.

“Mutations in the target gene (MP gene) can impair the diagnostic performance of influenza screening tests and thus produce false negative test results,” explains Dr. Andreas Simons, Head of Product Management at R-Biopharm. “Comparison of the detection systems we used with the described sequences of the two new virus variants showed no discrepancies. Their reliable detection is not affected by the described mutations.”

This means laboratories can continue to reliably confirm or rule out influenza infections using R-Biopharm’s RIDA®GENE tests (PG0505, PG0545, PG6825). The tests are real-time multiplex RT-PCR for direct qualitative detection of viruses.

About R-Biopharm

R-Biopharm AG, based in Darmstadt, is one of the leading biotechnology companies in Germany. The company, founded in 1988, is a second-generation family-owned company and is considered a pioneer in the field of health and quality of life. Its requirement: to ensure the highest possible accuracy, safety, clarity and certainty in prevention, therapy and treatment. To this end, R-Biopharm develops technologies, products and solutions for clinical diagnostics, nutritional care and analysis of food and feed – in internationally recognized top quality. R-Biopharm is the world leader in the market of test systems for allergen analysis.

R-Biopharm combines research, development and sales under one roof with the aim of responding to new challenges with agile processes and accompanying the ever-growing world population into a new age of health. The company is represented in more than 120 countries – 29 subsidiaries and 120 distributors. It employs approximately 1,400 people worldwide (690 at the headquarters in Darmstadt) and has received the “Sustainability Award” several times for sustainable and profitable growth.

Contact for printing:

Simona Feilerová
Head of corporate brand communication
R-Biopharm AG
On the new mountain road 17
64297 Darmstadt
Phone: 0 61 51 – 81 02-538
Email: s.feiler@r-biopharm.de
https://r-biopharm.com/de/
https://r-biopharm.com/de/kontakt/presse/
https://r-biopharm.com/de/news-presse/download-galerie/

Leave a Comment